Mitochondria as therapeutic targets for cancer chemotherapy.
Level 5 - mechanism / opinion, no new human data
Narrative review describing pharmacological mechanisms and preclinical strategies without new human data
PubMed 16892093 · doi:10.1038/sj.onc.1209598
What was done
This narrative review synthesized theoretical and experimental evidence on targeting mitochondrial bioenergetics and apoptosis mechanisms for cancer chemotherapy. It evaluated strategies focused on inducing mitochondrial outer membrane permeabilization (MOMP), overcoming endogenous apoptosis inhibition, and utilizing diverse chemical classes (such as BH3 mimetics, alpha-helical peptides, ampholytic cations, metals, steroid-like molecules, and IAP/HSP70 inhibitors) as monotherapies or chemosensitizers.
What was found
The abstract provides no quantitative metrics or empirical numbers. It reports qualitatively that chemically diverse agents can directly trigger MOMP to induce apoptosis or bypass resistance to DNA-damaging chemotherapeutics, and that molecules mimicking endogenous mitochondrial mediators (such as Smac/DIABLO and AIF) neutralize downstream inhibitors of apoptosis.
Why it matters
The review outlines how bypassing upstream signaling defects by directly targeting mitochondrial death machinery can serve as a strategy to overcome standard chemoresistance in oncology.
Limits
The abstract describes a narrative review with no original experimental data, systematic search methodology, or clinical trial results. No specific efficacy, toxicity, pharmacokinetic, or sample size parameters are reported.
Cited by
- supports Mitochondria trigger apoptosis and possess a veto mechanism over cell survival or cell death.